TY - JOUR
T1 - Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6
AU - Rojas, Manuel
AU - Rodríguez, Yhojan
AU - Monsalve, Diana M.
AU - Pacheco, Yovana
AU - Acosta-Ampudia, Yeny
AU - Rodríguez-Jimenez, Mónica
AU - Molano-González, Nicolás
AU - Mantilla, Rubén D.
AU - Ramírez-Santana, Carolina
AU - Anaya, Juan Manuel
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2019/7/1
Y1 - 2019/7/1
N2 - OBJECTIVES: Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. METHODS: Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. RESULTS: Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. CONCLUSIONS: The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
AB - OBJECTIVES: Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. METHODS: Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. RESULTS: Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. CONCLUSIONS: The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
UR - http://www.scopus.com/inward/record.url?scp=85059307721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059307721&partnerID=8YFLogxK
M3 - Review article
C2 - 30652681
AN - SCOPUS:85059307721
SN - 0392-856X
VL - 37
SP - 15
EP - 22
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 4
ER -